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of age, many parents believe the immunizations received at this time are causally associated. 5 The Measles-Mumps-Rubella vaccine (MMR) has unquestionably received the most scrutiny, as it is first scheduled to be given during the same time interval --between 12 and 18 months. 6 Additionally, up to 1/3 of patients with autism exhibit some form of regression 7 usually reported in the second year of life, again temporally correlating with the MMR vaccination.
The goal of this paper is to examine the evidence for a causal association between the MMR vaccine and autism. Thus literature will be reviewed regarding (1) the initial hypothesis of a causal link between the MMR vaccine and autism; (2) the epidemiological data regarding the correlation between MMR and autism; and (3) the controversy surrounding the ethylmercury containing additive thimerosal which has also been suggested to be an etiological factor in autism.
THE MMR VACCINE, AUTISM AND THE ASSOCIATION WITH

GASTROINTESTINAL DISEASE
The controversy surrounding the association between the MMR vaccine and autism began in 1998 with a paper published by AJ Wakefield and colleagues 8 in The Lancet. He examined 12 children with a history of normal development followed by regression co-existing with gastrointestinal (GI) complaints. The various complaints noted included diarrhea, abdominal pain, bloating and food intolerance. Upon endoscopy, all 12 children were found to have abnormalities ranging from lymphoid nodular hyperplasia to aphthoid ulceration. Wakefield also stated that the onset of behavioural symptoms was correlated with the MMR vaccine in 8 of the 12 children. Wakefield had previously suggested a link between inflammatory bowel disease (IBD) and the MMR vaccine 9 and commented on a possible link between the GI inflammation observed in the autistic population and the MMR vaccine.
Wakefield and colleagues 10 subsequently published a further article that examined 60 children with various developmental disorders (ranging from autism to dyslexia) and symptoms including abdominal pain, diarrhea, constipation and bloating. He found that 93% had ileocolonic lymphoid nodular hypoplasia (as compared to 14.3% of controls), however, no direct link to the MMR vaccine is discussed in the article and the suggestion that measles virus may be causative is only alluded to.
Since then, Wakefield has been more vocal regarding the relationship between MMR and autism. Before an American Academy of Pediatrics committee, 11 he proposed that changes in intestinal permeability may allow neurotoxic intestinal products to cross the blood-brain barrier, which may be particularly susceptible during early development. He suggested that the MMR vaccine, representing an atypical pattern of measles exposure, might cause an increased risk for intestinal infection which may in turn lead to developmental regression. He also stated that monovalent vaccines would have a decreased risk as opposed to the typical MMR vaccine due to a decreased challenge to a vulnerable immune system. He summarized by stating that 11 ". . . the widespread use of MMR immunization is a major determinant of the apparent increase in rates of autism".
There has, however, been a lack of evidence to support the claims that MMR is causally associated with autism. In addition, there is no convincing evidence that monovalent vaccines pose fewer challenges to the developing immune system. Wakefield's 12 findings of measles virus RNA in bowel disease have been supported by one report 13 which looked at autism in particular, but have not been substantiated by others, 14, 15 thus making it difficult to draw any conclusions regarding the association between measles virus and GI disease. One study showed evidence of altered measles immunity in children with autism, 16 although these positive results have been called into question due to issues of cross-contamination, as well as the use of unsubstantiated and un-validated biochemical techniques. 17 A severe blow to the autism-MMR hypothesis was dealt in a 2004 article in the Sunday Times. It stated that up to five of the patients in Wakefield's original study were involved in a lawsuit against vaccine manufacturers prior to their participation in the study. As well, it was stated that Wakefield received up to 55,000 British pounds to assist their case by finding evidence linking autism with the MMR vaccine. 18 In March of 2004, ten of the original authors of the 1998 Lancet article issued a retraction of the "interpretation of their findings", 19 in part due to these allegations of research misconduct by Wakefield. The authors emphasized that a causal link was not established in their 1998 paper but acknowledged that the possibility of such a link has since been raised, and that this may have had implications for public health on a global scale. They subsequently agreed to ". . . formally retract the interpretation placed upon the findings in this paper. . ."
EPIDEMIOLOGICAL EVIDENCE REFUTING A CAUSAL ASSOCIATION BETWEEN AUTISM AND THE MMR VACCINE
The bulk of the evidence refuting a causal link between the MMR vaccine and autism has come from epidemiologic research. 20 Most make use of health maintenance organizations or national databases to retrospectively examine evidence for a causal association.
The most compelling evidence for a lack of association comes from Madsen et al 21 who performed a retrospective cohort study on 537,303 children born between 1991 and 1998 in Denmark using the Danish Civil Registration system. Madsen identified cohorts of children who had been vaccinated against MMR (440,655 children) and those who had not been (96,648 children). They found no increased risk of autistic disorder or autistic spectrum disorder in the vaccinated compared to the unvaccinated groups.
Taylor et al 22 looked for any evidence of any changes in the incidence of autism or age at diagnosis of autism associated with the introduction of the MMR vaccine in the United Kingdom (UK) in 1988. They found an overall increase in the incidence of autism, unrelated to the MMR vaccine. They found no sudden increase or "step up" in the incidence of autism after the introduction of the vaccine, nor did they find a difference in age in diagnosis of autism between vaccinated and unvaccinated children. Developmental regression was not found to be clustered in the months after vaccination.
Similar time trend analyses by Kaye et al 23 and Dales et al 24 supported these findings. In particular Kaye also found an increase in the incidence of autism between 1988-1993 in the UK while the rate of vaccination remained the same. Dales' study reported an increase in the reports of children receiving services for autism spectrum disorders occurring in the late 1980's and 1990's, long after the MMR vaccine was introduced in the United States. A recent Japanese study 25 found that in a population which was experiencing decreasing rates of MMR vaccination, the incidence of autism actually increased.
A matched case-control study by Smeeth et al 26 also found that MMR vaccination was not associated with an increased risk of being diagnosed with a pervasive developmental disorder. Makela et al 27 using a retrospective design looking at 535,544 children in Finland also found no clustering of hospitalizations for autistic disorders after MMR vaccination. There were also no reports of autistic children making hospital visits for inflammatory bowel disease.
Many other studies focused on whether a "new-variant" of autism exists, 17 namely one which occurs after MMR vaccination and specifically shows regression and GI disturbance. Fombonne and Chakrabarti 28 found no increase in the "regressive" form of autism before and after the introduction of MMR in the UK. The mean intervals from parental recognition of autistic symptoms were comparable in those with and without regression. They found no reports of inflammatory bowel disorder in children with autism and no association between developmental regression and GI symptoms. Another study, which reviewed 14 years of vaccine related adverse events in Finland, found that none of the children who developed GI disturbance after MMR vaccination went on to develop autism. 29 This is supported by Black et al 30 who found no evidence that children with autism were more likely to have GI disorders prior to the diagnosis of autism. Taylor 31 also examined this issue and did not find an increase in the percentages of children with autism who had GI tract symptoms or developmental regression after the introduction of the MMR vaccine.
THIMEROSAL, AUTISM AND THE ISSUE OF POSSIBLE MERCURY POISONING
Thimerosal is an organic compound of ethyl mercury used as a preservative to prevent vaccine multi-dose vials from bacterial and fungal contamination. In 1998 the US Food and Drug administration reviewed thimerosal containing products and concluded that, theoretically, with the number of vaccines given in the first six months of life, the recommended Environmental Protection Agency (EPA) guidelines for mercury ingestion could be exceeded. 32, 33 The Food and Drug administration recommended that manufacturers remove thimerosal as much as possible from vaccines. Since 2001, thimerosal present in amounts large enough to act as a preservative have been removed from all childhood vaccines except for a few influenza and hepatitis vaccines. 34 In Canada, the most common childhood vaccines have been free from thimerosal since 1992. The only exception to this is the infant Hepatitis B vaccine which contains amounts of mercury well below most safety estimates. 5, 35 One must bear in mind however that these guidelines referred to methylmercury, not ethylmercury, and that inferring that one compound acts similarly to the other may not be entirely appropriate. 36 As well, methylmercury is transported across the blood-brain barrier via an active transport system, whereas ethyl mercury is not. Thus methylmercury is far more likely to cause nervous system toxicity. 37 Similar to the MMR-autism story, the controversy concerning a link between thimerosal and autism essentially began with a single article. This paper, published by Bernard et al 38 in Medical Hypotheses, questioned whether autism is in fact a novel form of mercury poisoning. They suggest that certain features of methylmercury exposure and autism are similar, including clinical and biological traits.
As stated by Nelson and Bauman 36 in their critique of the Bernard article --Bernard et al do not distinguish between typical and rare manifestations when comparing the clinical features of methylmercury poisoning to autism. The most common motor manifestations of mercury toxicity are ataxia, dysarthria and tremor, whereas in autism, the most common motor findings are sterotypies. As well, bilateral constriction of visual fields, while being characteristic in mercury poisoning, is not seen in autism. Early exposure to mercury usually leads to a small head size and microcephaly, whereas children with autism tend to have larger heads than the rest of the population. They also note that rates of autism did not increase after epidemics of mercury poisoning, such as the one occurring in the 1950's in Minimata, Japan. 36 In a 2004 study by Ip et al, 39 mercury levels were compared between autistic children and controls using a cross-sectional cohort design. The authors found no significant differences between hair and blood mercury levels between the two groups. These findings were in keeping with Pichichero et al 40 who compared children exposed to thimerosal in vaccines to an unmatched control group who had never had thimerosal in vaccines. They found no elevation in blood mercury levels in either group. Additionally, Holmes et al 41 looked at mercury levels in first baby haircuts in children with autism and in fact found levels to be lower in autistic patients as compared to controls. The authors however interpreted this as evidence of impaired excretion of mercury as opposed to evidence of toxicity.
A number of epidemiologic and ecologic studies have been conducted regarding the possible association between autism and thimerosal. 32 One study by Geir and Geir, 42 using the Vaccine Adverse Events Reporting System (VAERS) in the US, did show an increase in neurodevelopmental disorders (autism, mental retardation and speech disorders) after receipt of thimerosal containing vaccines. However, as Parker et al 32 point out in their review of Geir's paper, there were multiple methodological concerns with the paper, seriously calling into question the validity of their conclusions. One problem is that the VAERS is a passive reporting, system; thus anyone can report an adverse event after vaccination, including health care providers, parents, patients etc. Another concern is that the diagnoses are never validated. Additionally, although certain adverse events, such as anaphylaxis, are mandatory by US law to report, autism and neurodevelopmental disorders are not. The authors also did not state how they abstracted symptom terms from the VAERS or how they dealt with diagnostic overlap or incomplete records. 32 Parker et al 32 point out that "reporting bias" may also have been present if parents were aware of a possible link between thimerosal exposure and autism and "diagnosing bias" might have caused health care providers to be more likely to diagnose autism in those exposed to thimerosal.
One study using computerized Health Maintenance Organization databases was unable to confirm or refute an association between thimerosal and neurodevelopmental disorders. 43 Another cohort study again used the Danish Civil Registration System, 44 but this time to look at the rate ratio of Autism in children who received thimerosal containing vaccines versus those containing thimerosal-free vaccines. The authors, found no association between thimerosal containing vaccines and autism, and additionally found no evidence of a dose 45 used a retrospective cohort methodology in the UK and found no increase in developmental disorders associated with the use of thimerosal containing vaccines. They did find an increased risk of tics with increasing thimerosal dose, although the authors felt this was a chance effect or the result of confounding factors.
Finally an ecological study 46 looked at various time periods in Denmark: 1961-1970, when the cumulative ethylmercury dose was 200 µg in the first 15 months of life; 1970-1992, when the dose was 125 µg in the first 10 months of life; and 1992-2000 when vaccines did not contain thimerosal. They found the incidence of autism was stable until 1990 and then increased, most notably during the period when thimerosal was no longer used. Thus the authors concluded that there was no association between thimerosal containing vaccines and autism.
A few studies have found abnormalities in the biochemical pathways involved in the metabolism of methionine, homocysteine and glutathione. 47 Some have extrapolated that these abnormalities may underlie the reason why some siblings of autistic children are at a greater risk for autism. Others have attempted to show that thimerosal can cause low levels of glutathione 48 and can inhibit the activation of methionine by insulin-like growth factor-1 and dopamine. 49 However these studies have significant flaws including using extremely high doses of thimerosal (much higher than would be found through vaccines), using an in vitro instead of in vivo model, and using a neuroblastoma cell line instead of using a cell line derived from the developing central nervous system.
Because glutathione has a role in eliminating toxic substances from the body, some believe that a deficiency could cause autistic children to have predisposition to ethylmecury toxicity from thimerosal. This is largely unfounded, as glutathione is a relatively weak mercury chelator and does not have a much greater affinity for mercury than the body tissues as a whole. Nevertheless, some parents and researchers have advocated using chelation therapy for children with autism. For example, EDTA, while widely used as chelation therapy in autistic patients, in fact has a low affinity for mercury and is poorly absorbed in the oral form. The two main agents that act as effective mercury chelators are DMPS (2,3-dimercaptopropane-1-sulfonate) and DMSA (2,3-dimercaptosuccinic acid). DMSA is an approved and relatively safe treatment lead toxicity in children, while DMPS has potentially more toxicity. However DMSA is not without potential serious adverse reactions including rash, bone marrow suppression and liver toxicity. Some practioners have begun to use a transdermal preparation of DMSA to treat autisitc patients; however since DMSA is watersoluble, it does not dissolve well in water or oil and thus would likely not be absorbed well through the skin.
Based on the lack of evidence for mercury being a causative agent, the use of chelation therapy is not evidence-based. Even if mercury toxicity was the cause of autism, chelation therapy does not reverse the cerebral damage done by previous exposure, it only prevents further damage. There is currently no evidence for the value of chelation therapy in autism and thus evidence based recommendations would not support the use of chelation therapy in these patients. Indeed, some feel this treatment may in fact be unsafe. 50 In August 2005, a five-year-old autistic child died after receiving chelation therapy. 51
CONCLUSIONS AND IMPLICATIONS
The bulk of the evidence suggests no causal relationship between the MMR vaccine and autism, and Wakefield's initial hypothesis has been refuted by numerous well-designed studies. Additionally, no consistent link between gastrointestinal disorders, the MMR vaccine and autism has been shown.
Similarly, the lack of an association between thimerosal and autism has also been convincingly demonstrated. As well, since the use of thimerosal in vaccines in the United States is minimal and is even less of an issue with respect to Canadian vaccines, the argument against vaccination based on the grounds of "mercury poisoning" is not warranted. This is particularly true when one considers that the incidence of autism has continued to rise while the use of thimerosal has declined.
Statements and reviews by the Canadian Pediatric Society, 3 the American Academy of Pediatrics, 11 and the World Health Organization 52 have been published supporting the continued use of the MMR vaccine and agreeing that the evidence to date does not support an association between the vaccine and autism. As well, an independent review and the Institute of Medicine in the United States has concluded that neither the MMR vaccine nor thimerosal is associated with autism. 53 Despite this, parents continue to have concerns regarding the safety of vaccines. In a 2000 survey, more than 50% of parents of autistic children felt that vaccines were the main causal factor in autism. 11 There are numerous groups, largely made up of parents of autistic children, who strongly believe that vaccines were causative in their child's autism. They include Generation Rescue (www.generationrescue.org), SafeMinds (www. safeminds.org) and Moms against Mercury (www.moms againstmercury.org). The following is a statement by Moms against Mercury founder Amy Carson, from the organization's website, and represents a typical parent perspective:
"My son was born a healthy child. As time went on and the more he was vaccinated, the more he started to change. Not knowing that mercury was in vaccines until he was four years old, I had no idea what was truly wrong with him . . . I was outraged that I was not told that the most powerful neurotoxin was going to be injected in my new born child. It has devastated and changed our lives forever. . . I am dedicated to advocating for safer and mercury free vaccines and helping to educate parents by raising awareness of the mercury and the other dangerous ingredients in our vaccines." 54 Decreased uptake of immunizations have resulted in an increase in wild measles outbreaks. These outbreaks can and do still occur in Canada, usually among non-immunized persons. 55, 56 In the United Kingdom, uptake of MMR vaccination fell from 92% in 1995-96 to 82% in 2002-3 57 and measles outbreaks have subsequently occurred. 58 What can be done to reverse this dangerous trend? Firstly, health care practitioners must take parents' concerns seriously and be prepared to listen to their viewpoints. Presenting the evidence for safety as well as the risks of delaying vaccination seem to be the most effective strategies when informing parents. Health care providers can review the key points outlined in this article (Table) and consider giving caregivers previously published "Guides for Parents". 5 Many parents get their information from the internet, thus one should consider directing parents to the website of the Canadian Coalition for Immunization Awareness and Promotion (www.immunize.cpha. ca) or www.immunize.org, both of which contain links to various internet resources for parents regarding vaccine safety. Awareness and education should eventually help parents to be comfortable in making the best choices for their children in terms of giving routine vaccinations at suggested times.
Table: Summary of Key Points Regarding Immunizations and Autism
The incidence of autism has been increasing There is no convincing biological evidence that the measles virus or the MMR vaccine is related to autism Thimerosal has been absent from Canadian vaccines since 1992 (save for some influenza and hepatitis vaccines)
There is no convincing evidence that the ethylmercury found in thimerosal has an etiological role in autism Chelation therapy is an unproven and potentially dangerous therapy for children with autism
